Compare the Pharmacokinetics and Safety of CKD-333 With Co-administration CKD-330 and D090 in Healthy Male Adults

February 21, 2019 updated by: Chong Kun Dang Pharmaceutical

An Open-label, Randomized, Fasted, Single-dose, Three-way Crossover Study to Compare the Pharmacokinetic Characteristics and Safety Between Administration of CKD-333 and Coadministration of CKD-330 and D090 in Healthy Male Adults

The object of clinical trial is to investigate the pharmacokinetics and safety compared to CKD-333 and co-administration CKD-330, D090 under fasting condition in healthy male adults.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Unknown

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

An open-label, randomized, fasted, single-dose, three-way crossover study to compare the pharmacokinetic characteristics and safety between administration of CKD-333 and coadministration of CKD-330 and D090 in healthy male adults

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Anticipated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
36

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

19 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  1. Healthy male adults aged 19 to 45 years
  2. Body weight more than 50kg and within ideal body weight ±20%
  3. signed informed consent form

Exclusion Criteria:

  1. Have clinical significant medical history or disease that cardiovascular system, respiratory system, kidney, endocrine system, hematological system, digestive system , mental illness
  2. Have a gastrointestinal disease history that can effect drug absorption or surgery
  3. Systolic Blood pressure≥140mmHg or Systolic Blood pressure<90mmHg, Diastolic Blood Pressure≥90mmHg or Diastolic Blood Pressure<60mmHg

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Group 1
  • Period 1: CKD-333, formula I
  • Period 2: CKD-333, formula II
  • Period 3: CKD-330, D090
Drug: CKD-333, formula I
Test drug
Drug: CKD-333, formula II
Test drug
Drug: CKD-330, D090
Reference Drug
Experimental: Group 2
  • Period 1: CKD-333, formula I
  • Period 2: CKD-330, D090
  • Period 3: CKD-333, formula II
Drug: CKD-333, formula I
Test drug
Drug: CKD-333, formula II
Test drug
Drug: CKD-330, D090
Reference Drug
Experimental: Group 3
  • Period 1: CKD-333, formula II
  • Period 2: CKD-330, D090
  • Period 3: CKD-333, formula I
Drug: CKD-333, formula I
Test drug
Drug: CKD-333, formula II
Test drug
Drug: CKD-330, D090
Reference Drug
Experimental: Group 4
  • Period 1: CKD-333, formula II
  • Period 2: CKD-333, formula I
  • Period 3: CKD-330, D090
Drug: CKD-333, formula I
Test drug
Drug: CKD-333, formula II
Test drug
Drug: CKD-330, D090
Reference Drug
Experimental: Group 5
  • Period 1: CKD-330, D090
  • Period 2: CKD-333, formula I
  • Period 3: CKD-333, formula II
Drug: CKD-333, formula I
Test drug
Drug: CKD-333, formula II
Test drug
Drug: CKD-330, D090
Reference Drug
Experimental: Group 6
  • Period 1: CKD-330, D090
  • Period 2: CKD-333, formula II
  • Period 3: CKD-333, formula I
Drug: CKD-333, formula I
Test drug
Drug: CKD-333, formula II
Test drug
Drug: CKD-330, D090
Reference Drug

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
AUClast of Candesartan
Time Frame: 0 hour ~ 72 hour after drug administration
Area under the plasma concentration-time curve to last concentration of Candesartan
0 hour ~ 72 hour after drug administration
AUClast of Amlodipine
Time Frame: 0 hour ~ 72 hour after drug administration
Area under the plasma concentration-time curve to last concentration of Amlodipine
0 hour ~ 72 hour after drug administration
AUClast of Atorvastatin
Time Frame: 0 hour ~ 72 hour after drug administration
Area under the plasma concentration-time curve to last concentration of Atorvastatin
0 hour ~ 72 hour after drug administration
Cmax of Candesartan
Time Frame: 0 hour ~ 72 hour after drug administration
Maximum plasma concentration of Candesartan
0 hour ~ 72 hour after drug administration
Cmax of Amlodipine
Time Frame: 0 hour ~ 72 hour after drug administration
Maximum plasma concentration of Amlodipine
0 hour ~ 72 hour after drug administration
Cmax of Atorvastatin
Time Frame: 0 hour ~ 72 hour after drug administration
Maximum plasma concentration of Atorvastatin
0 hour ~ 72 hour after drug administration

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
AUCinf of Candesartan
Time Frame: 0 hour ~ 72 hour after drug administration
Area under the plasma concentration-time curve from zero to infinity concentration of Candesartan
0 hour ~ 72 hour after drug administration
AUCinf of Amlodipine
Time Frame: 0 hour ~ 72 hour after drug administration
Area under the plasma concentration-time curve from zero to infinity concentration of Amlodipine
0 hour ~ 72 hour after drug administration
AUCinf of Atorvastatin
Time Frame: 0 hour ~ 72 hour after drug administration
Area under the plasma concentration-time curve from zero to infinity concentration of Atorvastatin
0 hour ~ 72 hour after drug administration
AUCinf of 2-hydroxy atorvastatin
Time Frame: 0 hour ~ 72 hour after drug administration
Area under the plasma concentration-time curve from zero to infinity concentration of 2-hydroxy atorvastatin
0 hour ~ 72 hour after drug administration
Tmax of Candesartan
Time Frame: 0 hour ~ 72 hour after drug administration
Time to maximum plasma concentration of Candesartan
0 hour ~ 72 hour after drug administration
Tmax of Amlodipine
Time Frame: 0 hour ~ 72 hour after drug administration
Time to maximum plasma concentration of Amlodipine
0 hour ~ 72 hour after drug administration
Tmax of Atorvastatin
Time Frame: 0 hour ~ 72 hour after drug administration
Time to maximum plasma concentration of Atorvastatin
0 hour ~ 72 hour after drug administration
Tmax of 2-hydroxy atorvastatin
Time Frame: 0 hour ~ 72 hour after drug administration
Time to maximum plasma concentration of 2-hydroxy atorvastatin
0 hour ~ 72 hour after drug administration
T1/2 of Candesartan
Time Frame: 0 hour ~ 72 hour after drug administration
Half-life of Candesartan
0 hour ~ 72 hour after drug administration
T1/2 of Amlodipine
Time Frame: 0 hour ~ 72 hour after drug administration
Half-life of Amlodipine
0 hour ~ 72 hour after drug administration
T1/2 of Atorvastatin
Time Frame: 0 hour ~ 72 hour after drug administration
Half-life of Atorvastatin
0 hour ~ 72 hour after drug administration
T1/2 of 2-hydroxy atorvastatin
Time Frame: 0 hour ~ 72 hour after drug administration
Half-life of 2-hydroxy atorvastatin
0 hour ~ 72 hour after drug administration
clearance of Candesartan
Time Frame: 0 hour ~ 72 hour after drug administration
Apparent clearance of Candesartan
0 hour ~ 72 hour after drug administration
clearance of Amlodipine
Time Frame: 0 hour ~ 72 hour after drug administration
Apparent clearance of Amlodipine
0 hour ~ 72 hour after drug administration
clearance of Atorvastatin
Time Frame: 0 hour ~ 72 hour after drug administration
Apparent clearance of Atorvastatin
0 hour ~ 72 hour after drug administration
clearance of 2-hydroxy atorvastatin
Time Frame: 0 hour ~ 72 hour after drug administration
Apparent clearance of 2-hydroxy atorvastatin
0 hour ~ 72 hour after drug administration
Vd/F of Candesartan
Time Frame: 0 hour ~ 72 hour after drug administration
Apparent volume of distribution of Candesartan
0 hour ~ 72 hour after drug administration
Vd/F of Amlodipine
Time Frame: 0 hour ~ 72 hour after drug administration
Apparent volume of distribution of Amlodipine
0 hour ~ 72 hour after drug administration
Vd/F of Atorvastatin
Time Frame: 0 hour ~ 72 hour after drug administration
Apparent volume of distribution of Atorvastatin
0 hour ~ 72 hour after drug administration
Vd/F of 2-hydroxy atorvastatin
Time Frame: 0 hour ~ 72 hour after drug administration
Apparent volume of distribution of 2-hydroxy atorvastatin
0 hour ~ 72 hour after drug administration

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Chong Kun Dang Pharmaceutical

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Seunghun Han, Ph.D., Department of Clinical Pharmacology, Seoul ST.Mary's Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 25, 2019

Primary Completion (Anticipated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 29, 2019

Study Completion (Anticipated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
April 6, 2019

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 20, 2019

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 20, 2019

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 21, 2019

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
February 22, 2019

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 21, 2019

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
February 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 170PK18039

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings